Christopher Sweeney

Christopher Sweeney is a Medical Oncologist at the Dana-Farber Cancer Institute.

Christopher is a Member of the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group-ACRIN, Alliance and the American Association for Cancer Research. Christopher's primary research interest is drug discovery and development. Christopher's academic focus is management of genitourinary malignancies, with a focus on prostate and testicular cancer. Christopher is a highly active contributor to his field, having served on the Editorial Board for ASCO's Journal of Clinical Oncology and the Program and Cancer Education Committees of the American Society of Clinical Oncology. Christopher has received peer reviewed funding from the National Institutes of Health and the Department of Defense.

Christopher is also a Member of the Scientific Advisory Boards of biotech companies in the United States and Australia.

Christopher received his MBBS degree from the University of Adelaide, South Australia in 1992 and completed an internship at the Royal Adelaide Hospital. Christopher did residency in internal medicine at Gundersen Lutheran Medical Center, La Crosse, Wisconsin and a fellowship in Hematology / Oncology at Indiana University Medical Center, where he was later appointed Associate Director for Clinical Research for the Simon Cancer Center. Christopher joined the Lank Center for Genitourinary Oncology at DFCI and Harvard Medical School in 2009.

Christopher Sweeney is the Medical Oncologist at Dana-Farber Cancer Institute, based in United States, North America. With a background in Communities, Christopher Sweeney has a rich history of leadership and innovation.Christopher Sweeney studied MBBS Medicine at The University of Adelaide. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.